David Fajgenbaum, MD, MBA, MSc, Associate Professor of Medicine at Penn Medicine and co-founder of Every Cure, led a team that developed artificial intelligence powered technology that matches rare diseases with existing medications. As one example, the pilot run of the company’s AI platform identified a TNF inhibitor as treatment for a Castleman disease patient who is now in remission. Every Cure aims to take its AI-driven approach into clinical trials and establish new treatments for other diseases. Read more here.